14.61

0.93% -0.1521

Zymeworks Inc. (ZYME)

Overview News Price History Option Chain Discussions Forecast

Zymeworks Inc. stock is traded at $14.61, with a volume of 160.05K. It is down -0.93% in the last 24 hours and up +16.33% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Previous Close:

$14.76

Open:

$14.7

24h Volume:

160.05K

Relative Volume:

0.36

Market Cap:

$1.00B

Revenue:

$62.71M

Net Income/Loss:

$-112.51M

P/E Ratio:

5.2171

EPS:

2.8

Net Cash Flow:

$-96.01M

1W Performance:

+6.73%

1M Performance:

+16.33%

6M Performance:

+58.94%

1Y Performance:

+96.80%

1-Day Range:

$14.37

$14.86

1-Week Range:

$12.39

$15.00

52-Week Range:

$6.83

$15.00

Zymeworks Inc. Stock (ZYME) Company Profile

Name

Zymeworks Inc.

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

604-678-1388

Address

1385 West 8th Avenue, Suite 540, Vancouver, BC

Employee

170

Twitter

@ZymeworksInc

Next Earnings Date

2024-10-31

Latest SEC Filings

ZYME's Discussions on Twitter

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-21-23	Resumed	Wells Fargo	Overweight
Jan-04-23	Reiterated	H.C. Wainwright	Neutral
Dec-20-22	Upgrade	Jefferies	Hold → Buy
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-04-22	Resumed	Wells Fargo	Overweight
May-05-22	Upgrade	Guggenheim	Neutral → Buy
Mar-15-22	Initiated	Evercore ISI	Outperform
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold
Mar-31-21	Initiated	Credit Suisse	Outperform
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-08-21	Resumed	H.C. Wainwright	Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-06-20	Initiated	SVB Leerink	Outperform
Jan-10-20	Initiated	Wolfe Research	Outperform
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy
Nov-20-19	Initiated	Guggenheim	Buy
Sep-30-19	Upgrade	Raymond James	Outperform → Strong Buy
Aug-30-19	Initiated	Stifel	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
May-11-18	Upgrade	Barclays	Underweight → Equal Weight
Mar-19-18	Initiated	Raymond James	Outperform

View All

Zymeworks Inc. Stock (ZYME) Latest News

06:47 AM

Zymeworks Launches Phase 1 Trial for ZW191 - TipRanks

06:47 AM

06:03 AM

Zymeworks Announces First Patient Dosed in Phase 1 Clinical - GlobeNewswire

06:03 AM

06:00 AM

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - StockTitan

06:00 AM

01:22 AM

Zymeworks (NYSE:ZYME) Sets New 52-Week High Following Analyst Upgrade - Defense World

01:22 AM

Nov 04, 2024

Zymeworks (NYSE:ZYME) Hits New 52-Week High on Analyst Upgrade - MarketBeat

Nov 04, 2024

Zymeworks stock soars to 52-week high of $14.08 amid robust gains - Investing.com India

Nov 04, 2024

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab (NASDAQ:ZYME) - Seeking Alpha

Nov 04, 2024

Zymeworks (NYSE:ZYME) Cut to Equal Weight at Wells Fargo & Company - Defense World

Nov 04, 2024

Zymeworks’ (ZYME) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Nov 04, 2024

Nov 03, 2024

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Simply Wall St

Nov 03, 2024

Earnings call: Zymeworks reports Q3 2024 results and pipeline progress - Investing.com

Nov 01, 2024

Zymeworks (NYSE:ZYME) Shares Gap DownShould You Sell? - MarketBeat

Nov 01, 2024

Zymeworks stock downgraded at Wells Fargo (ZYME:NASDAQ) - Seeking Alpha

Nov 01, 2024

Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook - Simply Wall St

Nov 01, 2024

Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year - Yahoo Finance

Nov 01, 2024